# Utilizing Medication Assistance Programs, Handling Off-Label Requests, Managing High Dollar Medications, and Other Financial Pearls

Niesha Griffith and Sarah Hudson-DiSalle Wednesday, March 1, 2017


### Workshop Objectives

- Identify the appropriate steps involved in the development and implementation of a Medication Assistance Program (MAP).
- Discuss metrics to assist with justification of a MAP and ongoing metrics to support program continuation.
- Explain the importance of having a policy for off-label uses of medication.
- Describe all resources that are necessary to prepare, submit, and manage an off-label medication claim.
- Describe the process to appeal denied claims for offlabel oral and intravenous therapies.


#### Workshop Outline

- Medication Assistance Program Justification
- Evolution of a Medication Assistance Program
- Precertification of Outpatient Chemotherapy and Supportive Care Medications
- High Dollar Medication Process and Utilization of Copay Programs
- Utilizing Copay Programs for Infused Products
- Development and Implementation of an Off-Label Medication Program
- Managing Denials and Appeals

# Medication Reimbursement and Patient Support Services for Oncology



#### **Growth of Services**



<sup>\*</sup>MAP — Medication Assistance Program for Un- and Under-Insured Patients

# Program Justification for Medication Assistance Services


### Background

- Large number of uninsured patients in the US
  - Approximately 28.5 million people are uninsured
  - Over two-thirds of uninsured are from working families
  - The uninsured have far less access to care than either the privately or publicly insured
  - Affordable Care Act may reduce numbers by 13 million
- The number of underinsured jumped to 30 million
  - Increased 60% since 2003
  - Middle income families showed the largest increase

#### **Uninsured Definition**

- Individuals or groups with no health insurance coverage who lack any medical, dental, prescription, or vision coverage which affects access to care<sup>1</sup>
  - Medically indigent
  - Working uninsured
- Gaps in coverage affect people of all ages, races, ethnicities, and income levels

#### Uninsured Are Eligible for Assistance Under the ACA



Total = 27.2 Million Nonelderly Uninsured

"Reasons Being Uninsured Among Uninsured Adults," The Henry J. Kaiser Family Foundation, accessed 12 August 2015, http://kff.org/report-section/adults-who-remained-uninsured-at-the-end-of-2014-issue-brief/ Disclaimer: KFF materials may be reprinted, in whole or in part, without written permission, as long as they are not altered

#### **Definition of Underinsured**

A more formal definition of underinsured individuals includes people who are insured all year but have at least one of the following qualifiers:

- Medical expenses greater than 10 percent of annual income
- An annual income less than 200 percent of the federal poverty level and medical expenses greater than 5 percent of annual income
- Health plan deductibles equal to or greater than 5 percent of annual income

Source: Issues facing America: Underinsured patients; Ryan M. Nunley, MD, and the Washington Health Policy Fellows AAOS *Now* March 2008 Issue

#### Who Are the Underinsured?

- Underinsured patients have some form of health insurance, but lack the financial ability to cover out-ofpocket healthcare expenses:
  - High deductibles and/or co-insurance
  - High copays
    - Specialty drug tiers
    - Formulary restrictions
- Many insurance plans disadvantage oral chemotherapy and other specialty medications by placing them into the highest tier of the plan's prescription program
  - Results in decreased drug costs for payers at the expense of patients

### **Underinsured - Patient Perspective**

 For those with an acute or chronic illness, being underinsured can be more catastrophic than being uninsured

#### A patient quote:

"Being underinsured is a lot like paying a car payment each month and not being allowed to drive the car."

### Groups of Underinsured Most at Risk

#### Medicare Beneficiaries

- Who do not qualify for Medicaid or Low-Income Subsidy for Medicare Part D
- Who have high cost medications covered under Part B and do not have a secondary payer

#### **Medicaid Beneficiaries**

Who have a high spend down

#### Commercial Coverage

- High deductibles/copays
- Formulary restrictions may require patients to pay partial or full cost for therapies not on formulary

#### **Veterans Affairs**

 Formulary restrictions may require patients to pay partial or full cost for therapies not on formulary

### Patient Assistance Programs

- Pharmaceutical Manufacturer Assistance Programs (PMAPs) provide medications at no cost or copay assistance to patients who meet specified criteria
- Require completion of forms
  - Proof of income information
  - Clinical information
  - Prescriber signature
  - Requirements vary from one company to another
- Can be accessed for:
  - "Take-home" medications (at no charge)
  - Inpatient/outpatient replacement medications
  - Copay assistance for take-home and outpatient clinicinfused medications

### **Patient Assistance Programs**

- Patient Barriers to Accessing PMAPs
  - Intimidating and overwhelming process, paperwork and websites
  - Require both clinical and financial information
  - Difficult to access healthcare providers for required signatures
- Health Care Organization Barriers
  - Limited personnel resources for accessing financial and clinical information, completing applications, and obtaining signatures

# Genesis of The Ohio State University Medication Assistance Program

- Financial losses identified in drug utilization and reimbursement project
- Budget for charity "take-home" medication was increasing at an alarming rate
- Case manager observations that patient discharges were often delayed due to discharge medication access issues
- Identified need for dedicated staff

### Program Justification *Then*

- Conduct analysis of self-pay inpatients and outpatients who received one or more high cost agents where manufacturer assistance programs could have been accessed during the past year (i.e., these claims were written off)
- Quantify charity dollars spent on assisting patients with take-home medications (oral, selfinjectable)
- Take 50% of the sum of the two figures above as a rough, extremely conservative estimate of savings/cost avoidance

### Program Justification *Then*

- Justification of first Medication Assistance Coordinator
  - 50% of the sum of inpatient/outpatient replacement and take-home charity = \$56,000
  - Goal Return on Investment (ROI) = 1
  - Employee began in 12/2001
  - Medication accessed by 6/30/2002 = \$677,676
    - 90 patients
    - 29 referring physicians

#### Program Justification Now

- Justification of *your* first Medication Assistance Coordinator
  - Use 50% of the sum of three things:
    - High dollar outpatient infused medication write-offs (copays and/or full medication write-off costs)
    - Charity dollars provided for take-home medication copays and/or full medication costs
    - Off-label medication write-offs

Note: This will be a conservative estimate without determining actual patient/indication eligibility for your analysis

- Goal ROI = 1

#### **Program Justification Pearls**

- Consider pilot program rather than full system implementation
- Target areas for greatest opportunity and of greatest need first
- Examples:
  - Greatest opportunity chemotherapy infusion clinic
    - high dollar medication replacement programs
    - take-home supportive care medication programs
    - potential for off-label infusion medications
    - oral chemotherapy copay and PMAPs
  - Greatest need hospital with highest percentage of uninsured or underinsured patients
    - likely to have a high percentage of return ED visits and readmissions


### Examples\*

- High Dollar
  - Eculizumab
  - Ipilimumab
- Off-Label
  - Bevacizumab for liver carcinoma
  - Rituximab for steroid-refractory graft vs. host disease


### Examples\*

- Copay Assistance
  - Oral: pazopanib, pomalidomide, dasatinib
  - Infusion: pegfilgrastim, bevacizumab, denosumab
- Uninsured
  - enoxaparin, ibrutinib, sunitinib
- Underinsured
  - Most branded oncology products

# Dollars Medications Accessed The James




# Medication Assistance Program Return On Investment The James




ROI=Value of Medications Accessed- Cost of Charity, FTE, Supplies, etc

Cost of Charity, FTE, Supplies, etc

# Dollars Medications Accessed University Hospital (UH)




# Medication Assistance Program Return On Investment University Hospital (UH)




ROI=Value of Medications Accessed- Cost of Charity, FTE, Supplies, etc

Cost of Charity, FTE, Supplies, etc

#### **Patients Assisted**



### Charity Prescription Costs\*



\*Does not include prescriptions filled through the Medication Assistance Program (MAP) office for purchased 340B medication & non-340B medication

### Total OSU Program Impact

- From December 2001 to June 2015
  - \$214 million in dollars of medication accessed
  - 44,535 applications submitted
  - 18,762 patients served

## Questions?